Medicine and Dentistry
Radiation Therapy
100%
Overall Survival
61%
Chemoradiotherapy
52%
Esophageal Cancer
48%
Proton Therapy
48%
Recurrent Disease
43%
Neoplasm
43%
Squamous Cell Carcinoma
36%
Diseases
34%
Pancreas Cancer
30%
Stereotactic Body Radiation Therapy
29%
External Beam Radiotherapy
28%
Rectum Cancer
25%
Cholangiocarcinoma
24%
Adverse Event
23%
Malignant Neoplasm
23%
Hepatocellular Carcinoma
20%
Pancreas Adenocarcinoma
19%
Chemoradiation Therapy
19%
Hazard Ratio
18%
Systematic Review
17%
Neoadjuvant Therapy
17%
Intraoperative Radiation Therapy
17%
Metastatic Carcinoma
16%
Cancer
16%
Systemic Therapy
15%
Progression Free Survival
13%
Quality of Life
13%
Intensity Modulated Radiation Therapy
13%
Distant Metastasis
12%
Anal Canal
11%
Seminoma
11%
Photon Therapy
11%
Radiation Oncology
11%
Disease Free Survival
11%
Kaplan Meier Method
10%
Adenocarcinoma
10%
Anal Cancer
10%
Lymph Node Metastasis
9%
Oncology
9%
Esophagus
9%
Esophagectomy
9%
Liver Transplantation
8%
Local Therapy
8%
Recurrence Free Survival
8%
Gastrointestinal Cancer
8%
Liver Tumor
8%
Colorectal Carcinoma
8%
Odds Ratio
8%
Lung Cancer
8%
Keyphrases
Esophageal Cancer
53%
Overall Survival
49%
Radiotherapy
37%
Radiation Therapy
36%
Combined Modality Therapy
33%
Surgical Resection
29%
Proton Beam Therapy
28%
External Beam Radiotherapy
26%
Chemotherapy
22%
Stereotactic Body Radiation Therapy
21%
Radium
21%
Appropriate Use Criteria
20%
Multi-institutional
19%
Chemoradiation
19%
Clinical Outcomes
17%
Hepatocellular Carcinoma
17%
Neoadjuvant Chemoradiotherapy (nCRT)
17%
Pancreas Cancer
17%
Multi-institutional Analysis
17%
Executive Summary
17%
Chemoradiation Therapy
16%
Confidence Interval
16%
Hazard Ratio
16%
Neoadjuvant Therapy
14%
Systemic Therapy
14%
Intraoperative Radiation Therapy
14%
Curative Intent
13%
Tumor
13%
Liver
12%
Patient Selection
12%
Malignancy
12%
Chemoradiotherapy
12%
Intensity-modulated Proton Therapy
12%
Resection
12%
Distant Metastasis
12%
Proton
12%
Mayo Clinic
11%
Disease-free Survival
11%
Stereotactic Body Radiotherapy
11%
Locally Recurrent Rectal Cancer
11%
Progression-free Survival
11%
Colorectal Cancer
11%
Local Control
10%
Liver Transplantation
10%
Anal Squamous Cell Carcinoma
10%
Anal Canal Carcinoma
10%
Acute Toxicity
9%
Locally Advanced
9%
Proton Therapy
9%
Gastrointestinal
9%